Who Paid My Doc
Paul Sorajja
Interventional Cardiology Phoenix, AZ Medical Doctor
NPI 1205809308 CMS profile 54824
755 E McDowell Rd Fl 4, Phoenix, AZ 85006
General payments
$1,092,366
Research payments
$30,559
Ownership & investment interest
$0
Research they led as principal investigator
$7,666,351
Through program year 2025, Paul Sorajja of Phoenix, AZ is reported in the CMS Open Payments database as having received $1,092,366 across 1,109 general payments and $30,559 in research payments paid to them. Separately, studies naming them as principal investigator received $7,666,351 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
12 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $52,918 | 130 | |
| 2025 | Research | $2,100 | 2 | |
| 2024 | General | $170,375 | 182 | |
| 2023 | General | $221,044 | 217 | |
| 2023 | Research | $1,050 | 2 | |
| 2022 | General | $194,186 | 166 | |
| 2022 | Research | $4,975 | 9 | |
| 2021 | General | $122,255 | 109 | |
| 2021 | Research | $6,656 | 5 | |
| 2020 | General | $220,174 | 129 | |
| 2019 | General | $111,414 | 176 | |
| 2019 | Research | $15,778 | 3 |
Beside peers
- Paul Sorajja
- Interventional Cardiology median
- Middle half of Interventional Cardiology
- National median
In program year 2025, general payments to Paul Sorajja were reported at $52,918. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.
Show as a table
| Year | Paul Sorajja | Interventional Cardiology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $111,414 | $1,097 | $329–$3,048 | $163 |
| 2020 | $220,174 | $473 | $161–$1,480 | $114 |
| 2021 | $122,255 | $677 | $233–$1,827 | $132 |
| 2022 | $194,186 | $978 | $333–$2,724 | $149 |
| 2023 | $221,044 | $1,136 | $382–$2,986 | $160 |
| 2024 | $170,375 | $1,181 | $395–$3,326 | $164 |
| 2025 | $52,918 | $1,092 | $366–$3,019 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 12 drugsPart D claims
267
Drug cost
$69,022
Branded share of claims
21.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 26 | $35,850 | |
| Eliquis Apixaban | Brand | 31 | $30,474 | |
| Torsemide | Generic | 46 | $554 | |
| Metoprolol Succinate | Generic | 19 | $490 | |
| Atorvastatin Calcium | Generic | 16 | $306 | |
| Amlodipine Besylate | Generic | 23 | $250 | |
| Lisinopril | Generic | 27 | $250 | |
| Losartan Potassium | Generic | 14 | $234 | |
| Rosuvastatin Calcium | Generic | 14 | $225 | |
| Carvedilol | Generic | 19 | $193 |
The 10 drugs with the highest cost, of 12 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 63 billing codesPaid by Medicare
$211,945
Medicare patients
420
Services billed
848
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 74% | |
| Heart failure | 60% | |
| Ischemic heart disease | 55% | |
| Atrial fibrillation | 50% | |
| Chronic kidney disease | 38% | |
| Arthritis | 36% | |
| Diabetes | 23% | |
| COPD | 18% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
1,130 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Interventional Cardiology in Arizona
Hursh Naik
Interventional Cardiology · Avondale, AZ
Thomas Waggoner
Interventional Cardiology · Tucson, AZ
Timothy Byrne
Interventional Cardiology · Phoenix, AZ
Haidar Yassin
Interventional Cardiology · Phoenix, AZ
Kapildeo Lotun
Interventional Cardiology · Tucson, AZ
Azimuddin Khawaja
Interventional Cardiology · Peoria, AZ
Related records
Interventional Cardiology in Arizona
Practitioners in the same specialty and state, ranked by reported value.
All Interventional Cardiology
Everyone recorded under this specialty, nationwide.
Doctors in Arizona
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.